Intec Pharma (NTEC) Receives European Patent Covering Accordion Pill Zaleplon

Go back to Intec Pharma (NTEC) Receives European Patent Covering Accordion Pill Zaleplon

Intec Pharma Further Expands Intellectual Property With a New Patent for the Accordion Pill Zaleplon in Europe

December 16, 2015 7:00 AM EST

JERUSALEM, ISRAEL -- (Marketwired) -- 12/16/15 -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European Patent Office (EPO) that a European patent will be granted December 23, 2015 on the Company's European Patent Application for a "Zaleplon gastroretentive drug delivery system."

The patent, number EP 237883, protects one of the Company's product candidates, Accordion Pill Zaleplon, that is being developed for the indication of treatment of... More